Navigation Links
Jennerex To Present at Rodman & Renshaw 10th Annual Healthcare Conference
Date:11/4/2008

SAN FRANCISCO, Nov. 4 /PRNewswire/ -- Jennerex, Inc. (San Francisco, CA and Ottawa, Canada) a clinical-stage biopharmaceutical company, today announced that David H. Kirn, M.D., President and Chief Executive Officer, will present an overview of the Company at the 10th Annual Rodman & Renshaw Healthcare Conference in New York on November 11, 2008 at 3:15 p.m. Eastern Time (12:15 p.m. Pacific Time) at the Palace Hotel, New York.

A webcast of the presentation will be available during the event at http://www.jennerex.com and will be archived and available on the website for 3 months.

About Jennerex

Jennerex is a clinical-stage biopharmaceutical company focused on the development and commercialization of first-in-class, breakthrough targeted oncolytic products for cancer. The company's lead product JX-594, currently in an international Phase 2 trial for primary liver cancer, demonstrated promising Phase 1 efficacy and safety results in patients with a diverse array of common large market cancers. Jennerex's products target, attack and eradicate cancers through a novel and potent oncolytic mechanism that is dependent on highly-specific replication of the company's poxviruses in cancer cells. These products simultaneously stimulate the body's immune response to the cancer. Of note, this mechanism of action and the results in patients to date put the company's product class in a leadership position. Jennerex's position is in marked contrast to gene therapy and standard cancer vaccine approaches. Jennerex Biotherapeutics was established in San Francisco and in Ottawa in 2006 with Dr. David Kirn (CEO) in San Francisco and Dr. John Bell (CSO) from the Ottawa Health Research Institute/University of Ottawa. For more information about Jennerex and the company's robust pipeline and three clinical-stage products, please visit http://www.jennerex.com.


'/>"/>
SOURCE Jennerex, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Jennerex Clinical Trial Data with JX-594 Selected for Plenary Session Presentation at Major International Conference
2. Hospira to Present at the 2008 Annual Credit Suisse Health Care Conference on November 12
3. Alexion to Present at Investor Conferences
4. IPC The Hospitalist Company, Inc. to Present at the 2008 Annual Credit Suisse Health Care Conference
5. Jazz Pharmaceuticals to Present at Investor Conferences
6. Senesco Technologies to Present at 10th Annual Rodman & Renshaw Healthcare Conference
7. XOMA to Present at the Rodman and Renshaw Annual Global Investment Conference on November 11
8. The Quantum Group Inc. To Present at Paulson Investments 31st Annual Westergaard Conference
9. Haemacure to Present at the Rodman & Renshaw Annual Global Investor Conference
10. Response Biomedical to Present at Rodman and Renshaw 10th Annual Healthcare Conference
11. BD to Present at Investor Healthcare Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... (PRWEB) , ... December 09, 2016 , ... Mediaplanet today ... for organ transplantation while encouraging readers to sign up as an organ donor for ... organ transplant. , An organ donor can save up to 8 saves through ...
(Date:12/9/2016)... ... December 09, 2016 , ... MEDI+SIGN®, a provider of fully-automated ... new solution for Emergency Departments (ED) has been added to their portfolio. Housed ... examination rooms, and with a simplified pallet of information available to the patient, ...
(Date:12/9/2016)... (PRWEB) , ... December 09, 2016 , ... ... program through the Pennsylvania Cable Network (PCN) during the summer of 2016. The ... Implementation Grant provided by the United States Department of Health and Human Services ...
(Date:12/8/2016)... FL (PRWEB) , ... December 08, 2016 , ... ... awarded accreditation with distinction by the Undersea and Hyperbaric Medical Society (UHMS), the ... with advanced care and patient safety. Only a few hospitals and facilities have ...
(Date:12/8/2016)... ... 08, 2016 , ... Russ DiGilio , founder and ... #QuackGivesBack campaign which supported local breast cancer organizations during National Breast Cancer Awareness ... Back initiative, and we’re very pleased with the participation in every franchisee’s ...
Breaking Medicine News(10 mins):
(Date:12/9/2016)... Pa. , Dec. 9, 2016 Department ... announced temporary regulations for medical marijuana dispensaries under Act ... Pennsylvania Bulletin , and are now available online ... is needed in the plan for operation; process for ... dispensary; as well as where the dispensary facilities can ...
(Date:12/8/2016)... VIEW, Calif. , Dec. 8, 2016 IRIDEX ... intends to offer newly issued shares of common stock, $0.01 ... pursuant to an underwritten public offering.  The final terms of ... the time of pricing, and there can be no assurance ... IRIDEX expects to use the net proceeds it ...
(Date:12/8/2016)... Dec. 8, 2016 KEY FINDINGS ... Patient warming ... of blood during surgeries, lowering the risks of neurological disorders ... of SSIs. The patient warming systems can be segmented into ... benefits in turn reduce the stay at hospitals thus, lowering ...
Breaking Medicine Technology: